Sarah Davis, MD
Medical Oncology · Aurora, CONPI 1659576163
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,510 of the $7,468 with a category attached, or 87.2%. 5 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 40.9% of the total.
Across 10 payments — averaging $746.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$3K
- AstraZeneca$2K
- Genentech USA, Inc.$2K
- Trisalus Life Sciences, Inc.$301
- Array Biopharma Inc$139
Across 276 payments — averaging $14,037 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$2.3M
- Merck$722K
- Pfizer$289K
- Genentech, Inc.$268K
- Astrazeneca UK Limited$148K
- AstraZeneca$37K
- plus $83K from 5 others
What the payments were for
- Consulting fees$6,51087%
- Food & beverage$95813%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 2 | $3,055 |
| AstraZeneca | 5 | $2,103 |
| Genentech USA, Inc. | 1 | $1,870 |
| Trisalus Life Sciences, Inc. | 1 | $301 |
| Array Biopharma Inc | 1 | $139 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPDIVO$3,000
- TECENTRIQ$1,870
- IMFINZI$1,775
- TRINAV INFUSION SYSTEM$301
How this compares
$7,468 in reported general payments places this provider in the 70th percentile of 96 medical oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Everolimus | 12 | $163,498 |
| CreonLipase/Protease/Amylase | 30 | $107,871 |
| XareltoRivaroxaban | 14 | $7,313 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 16 | $721 |
| LoperamideLoperamide Hcl | 14 | $482 |
| Ondansetron Hcl | 38 | $419 |
| Oxycodone Hcl | 24 | $382 |
| Morphine Sulfate ErMorphine Sulfate | 12 | $363 |
| Omeprazole | 22 | $348 |
| Potassium Chloride | 16 | $301 |
| Prochlorperazine Maleate | 15 | $168 |
| Alprazolam | 11 | $39 |
| Pantoprazole Sodium | 13 | $11 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Aurora
- David CamidgeAurora$648K
- Paul BunnAurora$354K
- Sapna PatelAurora$186K
- Sunnie KimAurora$81K
- Virginia BorgesAurora$68K
- Erin SchenkAurora$63K
- Karl LewisAurora$62K
- Jose PachecoAurora$50K
- Leonard GlodeAurora$49K
- Robert DoebeleAurora$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.